Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome

Prince of Songkla University39 enrolled

Overview

The purpose of this study is to evaluate the adjunctive effect of intratenon Bevacizumab on the result of trabeculectomy in primary term of intraocular pressure (IOP).

Prospective interventional clinical trial Single center, outcome assessor-masked, active control, randomized controlled trial

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Glaucoma

Interventions

BevacizumabDRUG

Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application

Mitomycin CDRUG

Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Primary open angle glaucoma with primary mmc-trabeculectomy indication Exclusion Criteria: * combined phacoemulsification with trabeculectomy * no more than 6 month of cataract surgery before trabeculectomy * revised trabeculectomy * active uveitic glaucoma * neovascular glaucoma * par planar vitrectomy * conjunctival surgery * allergy to bevacizumab or mitomycin C * ischemic heart disease * cerebrovascular disease * renal failure * liver failure

Locations (1)

Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University

Hat Yai, Changwat Songkhla, Thailand

Outcomes

Primary Outcomes

Intraocular pressure

Time frame: 6 month

Secondary Outcomes

Bleb characteristic grading

Time frame: 6 month

systemic Blood pressure

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.